Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.
Authors
Krebs, Matthew GSloane, Robert
Priest, Lynsey
Lancashire, Lee J
Hou, Jian-Mei
Greystoke, Alastair
Ward, Timothy H
Ferraldeschi, Roberta
Hughes, Andrew
Clack, Glen
Ranson, Malcolm R
Dive, Caroline
Blackhall, Fiona H
Affiliation
Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, Manchester, United Kingdom.Issue Date
2011-04-20
Metadata
Show full item recordAbstract
Lung cancer is the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) lacks validated biomarkers to predict treatment response. This study investigated whether circulating tumor cells (CTCs) are detectable in patients with NSCLC and what their ability might be to provide prognostic information and/or early indication of patient response to conventional therapy.Citation
Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. 2011, 29 (12):1556-63 J Clin OncolJournal
Journal of Clinical OncologyDOI
10.1200/JCO.2010.28.7045PubMed ID
21422424Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2010.28.7045